What did @d.dominiqiee actually say?
Honestly? It's not clear. The transcript from this video is a repeated, garbled phrase that reads like corrupted audio or a transcription failure: "made it mean it apart he'll drive a funky maybe you mean it apart he'll drive a funky." There is no intelligible claim here. The video is tagged under GLP-1 content, which tells us something about the intended subject matter, but not what was actually communicated.
This matters. With 394,600 views on a video about a class of medications that includes semaglutide and tirzepatide, the potential for health misinformation to spread is real. We can't evaluate what we can't hear. But we can use this as an opportunity to lay out what the actual science says about GLP-1 receptor agonists, so viewers who landed here have something reliable to work with.
Does the science back this up?
Since no verifiable claim was made, we can't apply a verdict to the creator's words. What we can do is address what GLP-1 content on TikTok typically asserts, because the platform has become one of the primary ways people learn about these drugs, for better or worse.
GLP-1 receptor agonists like semaglutide and tirzepatide are among the most studied weight management drugs in recent history. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide produced up to 22.5% mean body weight reduction over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced roughly 14.9% weight loss versus 2.4% with placebo. These are significant numbers, and the drugs genuinely work for the populations studied. That does not mean they work the same way for everyone, or that TikTok summaries of that data are accurate.
What did they get wrong (or right)?
We cannot assign a right or wrong to this creator specifically. The audio is unintelligible, and fact-checking a string of nonsense syllables would itself be irresponsible. What we can say plainly is this: a video with nearly 400,000 views that is tagged as GLP-1 health content carries real-world weight, regardless of whether the audio transferred correctly.
Common errors in the GLP-1 TikTok space that we see repeatedly include claims that compounded semaglutide is equivalent to brand-name Wegovy or Ozempic, that these medications "cure" diabetes or obesity, and that dosing is simple or universally applicable. All three of these framings are either clinically inaccurate or potentially dangerous. The FDA has explicitly stated that compounded drugs are not FDA-approved and should not be considered interchangeable with their branded counterparts.
What should you actually know?
If you found this video because you're researching GLP-1 medications, here is what the evidence actually supports. These drugs work by mimicking the glucagon-like peptide-1 hormone, slowing gastric emptying and reducing appetite signals in the brain. They are not magic. They require medical supervision, and side effects including nausea, vomiting, and in rare cases pancreatitis are documented in clinical literature (Davies et al., 2021, Lancet).
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown stronger weight loss outcomes than semaglutide in head-to-head data from the SURPASS-2 trial (Frías et al., 2021, New England Journal of Medicine), but individual response varies. Neither drug is appropriate for everyone, and neither should be started based on a TikTok video, audible or not. Talk to a licensed clinician who can review your full medical history before starting any GLP-1 therapy.